Categories Technology, U.S. Markets News

Google drops Chinese search engine plans for now

Alphabet Inc.’s (GOOGL) subsidiary Google is said to have shut down the development of a censored search engine for China, according to a report by The Intercept. The project had received backlash from the company’s employees who said it went against Google’s ethos.

The Chinese search engine project, termed Dragonfly, was reportedly one of top priority for the management team as China is a lucrative market. China has strict rules on censorship and to meet these requirements, the employees working on Dragonfly were reportedly developing blacklists, which would aid in blocking information on sensitive issues like democracy and human rights.

However, after Google’s privacy team came to know about this, the project was reported to have undergone some changes which in turn affected its progress. A large number of engineers were moved from the Dragonfly project to other projects related to Indonesia, Brazil and India.

Google works on censored China search engine

Google had planned to launch Dragonfly in early 2019 but the report said the protests and other issues appear to have forced the company to shelve it at least for the short term. Last week, when Google’s CEO Sundar Pichai was questioned by the Congress on the censored Chinese search engine, he said the company did not have plans to launch a search engine in China right now but did not rule out a future possibility.

Earlier this year, Google employees had opposed the company’s collaboration with the Pentagon on a project involving artificial intelligence capabilities and military drones. Google subsequently said it would not renew the contract after existing obligations were met.


We’re on Flipboard! Follow us to receive the latest stock market, earnings and financial news at your fingertips.

Most Popular

Cost reduction has become a priority for FedEx (FDX) after a challenging quarter

Shares of FedEx Corporation (NYSE: FDX) were up 1% on Tuesday. The stock has dropped 44% year-to-date and 34% over the past 12 months. The company delivered mixed results for

Prime Medicine is the next big biotech to pursue IPO. Here’s all you need to know

After a soft start to the year, the IPO market has witnessed muted activity so far though a few big companies entered the stock market. On the heels of AIG

Stock Watch: Is Darden Restaurants a good buy after earnings?

After a prolonged slowdown, the restaurant industry is returning to normal patterns but macroeconomic uncertainties and high inflation are currently playing spoilsport for it. While the pandemic-related slump forced many

Add Comment
Viewing Highlight